Thursday, March 29, 2018

Why It Pays to be Vigilant about Security

NewImage.png
 
 
While we all know how nefarious types are always working to steal or data and our cash, I don’t think it ever hurts to provide my readers with reminders of how aware we need to be of the potential for security breaches.
 
A recent arrest by Europol allowed them to get the mastermind behind a cyber scam that allowed the perpetrators to steal over 1 billion Euros.  How did the bad guys perpetrate this scam?  Here is the lowdown on the Modus Operandi from Europol:
 
In all these attacks, a similar modus operandi was used. The criminals would send out to bank employees spear phishing emails with a malicious attachment impersonating legitimate companies. Once downloaded, the malicious software allowed the criminals to remotely control the victims’ infected machines, giving them access to the internal banking network and infecting the servers controlling the ATMs. This provided them with the knowledge they needed to cash out the money.
 
 
So, in a nutshell, bank employees were targeted.  They were sent emails with links or attachments the seemed to come from legitimate sources.  However, when the file or link was opened, software was installed that gave the bad guys complete control over the computer, but was un-noticeable by the user.
 
Frightening?  You bet.  These guys made off with 10 billion Euros before they were caught.  And you KNOW that the financial industry is security conscious.  The lesson here is to always be vigilant.  You can’t be over paranoid when it comes to data security!
 

Wednesday, March 28, 2018

Study of Oral Moisturizers Concludes that OraCoat® XyliMelts® Contain One of the Safest pH Levels of any US OTC Dry Mouth Product

XyliMelts-Image.jpg

University of Florida Study of Eleven Brands of Lozenge-Type Oral Moisturizers Finds that Most have Dangerous Acidity Levels with XyliMelts being One of the Few Exceptions

 – Researchers at the University of Florida recently tested eleven brands of lozenge-type oral moisturizers for harmful acidity levels that cause tooth erosion. The study found that nine of the eleven tested products are acidic (pH less than 7) and cause tooth erosion. The only two lozenge-type dry mouth remedies that were non-acidic were OraCoat® XyliMelts® and Salese®.

The objective of the study was to measure pH levels, titratable acidity, and erosive effect of commercially distributed dry mouth lozenges and adhering discs on teeth, mainly the dentin which is exposed at the gumline. Each product was crushed into five grams of powder and dissolved in 10 mL of water. Acidity was measured with a calibrated pH meter. Titratable acidity was measured by adding sodium hydroxide until the solution reached neutrality. Erosion of tooth structure was measured by placing human teeth in the solution and measuring loss of mass.

In order of danger, the most dangerously acidic dry mouth lozenges and adhering discs were reported to be:

• DenTek® OraMoist®, pH 2.9
• Cotton Mouth Lozenges®, pH 3.1
• MedActive® Oral Relief Lozenges, pH 3.2
• Hager Pharma Dry Mouth Drops, pH 4.44
• Rite Aid Dry Mouth Discs, pH 5.1
• CVS Dry Mouth Discs, pH 5.3
• ACT® Dry Mouth Lozenges, pH 5.7
• TheraBreath Dry Mouth Lozenges, pH 5.82

Moreover, the oral moisturizers that caused the most tooth erosion were, in order:

• Cotton Mouth Lozenges, 3.1% loss
• DenTek OraMoist, 2.3% loss
• MedActive Oral Relief Lozenges, 1.1% loss
• Rite Aid Dry Mouth Discs, 1.1% loss
• CVS Dry Mouth Discs, 1.0% loss
• TheraBreath Dry Mouth Lozenges, 1.0% loss

The study found a robust statistical correlation between high acidity and tooth loss. Both remedies that passed the acidity test, XyliMelts and Salese, contain a pH level of 8.0, which is considered non-harmful to teeth. Previous studies reported that pH below 6.7 can be erosive to dentin. One of the products, XyliMelts discs, was recently revealed to reduce symptoms of Gastroesophageal Reflux Disease (GERD), which also causes tooth erosion. XyliMelts are oral adhering discs that contain 550 mg of xylitol for sweetness to stimulate saliva flow, cellulose gum to slow dissolution and lubricate the mouth, a layer of acacia gum to adhere to gingiva or teeth, and a small amount of calcium carbonate to neutralize acidity. XyliMelts used at night while sleeping is the most effective per gram delivery of xylitol to reduce tooth decay.
The complete study results are available at this link: https://cdn.shopify.com/s/files/1/0035/3832/files/Delgado_AADR_2018_Acidity_of_dry_mouth_lozenges.pdf?10451805702918068836
XyliMelts are available over the counter at Walmart, CVS, and Rite Aid. For more information on XyliMelts, visit www.oracoat.com.

About OraCoat
OraCoat is the world leader in the breakthrough technology of “oral adhering discs” which slowly release ingredients in the mouth and are safe for use while sleeping. The OraCoat® brand represents a family of products that solve oral care problems by coating the mouth with safe ingredients that become effective when they are slowly released. OraCoat’s leading products are XyliMelts® and XyliGel® OTC products for dry mouth. Other oral care solutions in the OraCoat family are planned. OraCoat’s innovative oral care solutions are backed by careful research based on medical science to ensure optimum performance and user safety.

 

Tuesday, March 27, 2018

Spring Cleaning for the Home Office

Spring Cleaning.jpeg
 
Did you know that 43% of Americans work from home at least *some* of the time?  Nope, me neither.  I saw that stat and was stunned by it.  Then I started thinking about it, and with our now blazing fast Internet speeds, it’s pretty easy to simply perform a remote login and get some things accomplished.  Of course, when you work from your home office, security is just as big an issue as it is when you are IN your office.  However, most of us take for granted the fact that our data is just as much at risk from home as from the office.  The problem is, that most folks don’t really think all that much about security, and consequently, leave themselves open to hacks, RansomWare, etc.
 
Those are big problems, but even bigger ones if you are dealing with sensitive data.  Therefore, if you are in healthcare, you have to approach HIPAA in the same manner at home as you would in your practice.
 
To that end, I came across a good article oni8 Security Spring Cleaning Tips for the Home Office. Kudos to the author Steve Zurier.  I think the article is definitely worth a read.

Monday, March 26, 2018

HealthFirst Upgrades Emergency Medical Kits with NARCAN®

HealthFirst Kit.png
 
HealthFirst is a U.S. company that, among other things, provides emergency medical kits for offices.  Many dental practices rely on their HealthFirst kit in the rare case of a medical emergency.  The kits were most commonly used for things like anaphylaxis or hypoglycemia.  However, with the increasing attention being paid to opiates in the U.S., the company is now starting to upgrade their kits (both new and existing) with NARCAN® (naloxone HCL).  The drug is being provided in a nasal spray.  NARCAN® is a rapidly absorbed opioid antagonist that binds to the same receptors as narcotics and displaces the narcotic molecules, resulting in a rapid overdose recovery.
 
Here is the info from HealthFirst:
 

HealthFirst proudly partners with you to keep your SM Series kit updated and ready for common medical emergencies. Our customers managed more than 1,000 medical emergencies in the last year.


Upgrading your kit with NARCAN® (naloxone HCl)
Working with our Medical Advisory Board, we regularly review our kits to make sure they meet current emergency needs. Because of the rapidly growing opioid crisis, the Board recommends adding NARCAN to the core set of SM Series kit medications.  

Despite your best efforts to keep patients safe, you can’t control the behavior of patients or their families. With NARCAN, you can help prevent your patients from becoming victims of the opioid epidemic.

IMPORTANT: HealthFirst will send you two NARCAN Nasal Sprays within the next 30 days, included with a regular replenishment shipment for your kit. 
Easy to use, special pricing

NARCAN Nasal Spray is easy to administer when timing is critical. HealthFirst offers you competitive pricing so this upgrade is as affordable as possible.

Important details
Your upgrade will arrive with your next medication replenishment shipment, within 30 days after this notice.
The upgrade will include two NARCAN Nasal Sprays and packaging to fit the units in your SM Series kit.
This upgrade, including the medications, is priced at $110.
For information on all medications in this shipment, please sign in to www.OnTraq.us and view Upcoming Shipments.
If you have questions, or do not wish to receive this update, please call (855) 300-1797 or email shipments@healthfirst.com.

Thursday, March 22, 2018

ADA Meeting in Honolulu Encourage Members to Get on Track with Head and Neck Cancer in Series at ADA 2018

ADA Logo.jpg
 
Oral and pharyngeal cancer is a scourge that needs to be eradicated.  Globally nearly 500,000 individuals will be diagnosed with this disease in 2018.  More than half of those individuals will die within 5 years.  Those that survive may very well suffer disfiguring surgeries that leave them, literally, with scars and injuries that are social and life changing.  To help find the disease earlier and with greater accuracy, the ADA is offering courses at this year’s meeting in Honolulu, Hawaii.
 
Here is info on this from the ADA News.  Make plans to attend at least one of these courses and help change the world.
 
 

A head and neck cancer track at ADA 2018 – America's Dental Meeting offers dental professionals ways to learn about their role in cancer screening, biopsy and management.

A course offered at two different times during meeting in Honolulu will help clinicians learn to deliver a complete oral cancer exam, perform simple biopsies in office and identify when to perform biopsies and when to refer. Simple Biopsy Techniques for the GP or Specialist will be held 7-10 a.m. (5204) and also 11:30 a.m.-2:30 p.m. (5214) on Oct. 18. Dr. Robert Convissar, director of laser dentistry at the New York Presbyterian Hospital of Queens, will lead the courses. 

Another course targets hygienists. What's New in Oral Cancer Screening? A Workshop for Dental Hygienists is scheduled for two different times — 7-10 a.m. (5222) and 11:30 a.m.-2:30 p.m. (5223) on Oct. 18.  Dr. Mark Lingen, a dentist with a Ph.D., a professor of pathology at the University of Chicago, Pritzker School of Medicine, and JoAnn Gurenlian, Ph.D., a hygienist, professor and graduate program director at Idaho State University will lead the course. 

Dr. Lingen and Dr. Theresa Hofstede, associate professor in the department of head and neck surgery in the division of surgery at the University of Texas MD Anderson Cancer Center, will lead the course Oral Cancer Screening and Radiotherapy Morbidity Management (6822). 

Participants will learn to conduct a comprehensive visual tactile exam and differential diagnosis of common oral lesions; discuss findings of ADA oral cancer screening guidelines; and define the role of dental professionals in identifying and managing radiotherapy related morbidities. This course is scheduled for 11:30 a.m- 2 p.m. Oct. 19.

Registration for ADA 2018 is open. To register for these courses or learn more about the meeting, visit ADA.org/meeting. 

Wednesday, March 21, 2018

Star ETorque Electric Handpiece System

NewImage.png
 
For the past 5 years or so I have been using electric handpieces almost exclusively.  I had tried them many years ago (almost 20 to be exact) and was less than overwhelmed.  However, the newer generations are simply incredible!  They are high torque, incredibly precise, and amazingly durable.
 
I will on occasion still pick up an air driven system, but it is a rarity.
 
The Star ETorque is the latest electric from DentalEZ.  If you are interested in more info, here is the link.  

Tuesday, March 20, 2018

Centers for Disease Control Report: Dental Personnel Treated for Idiopathic Pulmonary Fibrosis at a Tertiary Care Center — Virginia, 2000–2015

CDC-Logo.jpg
 
In the CDC’s Morbidity and Mortality Weekly Report (MMWR) from March 9, 2018 comes information on a respiratory disease that had a large “cluster” of dentists.  I’m not sure what this means for the profession at this point in time, but it definitely deserves reading at this point in time.
 
Here is the report:
 

In April 2016, a Virginia dentist who had recently received a diagnosis of idiopathic pulmonary fibrosis (IPF) and was undergoing treatment at a specialty clinic at a Virginia tertiary care center contacted CDC to report concerns that IPF had been diagnosed in multiple Virginia dentists who had sought treatment at the same specialty clinic. IPF is a chronic, progressive lung disease of unknown cause and associated with a poor prognosis (1). Although IPF has been associated with certain occupations (2), no published data exist regarding IPF in dentists. The medical records for all 894 patients treated for IPF at the Virginia tertiary care center during September 1996–June 2017 were reviewed for evidence that the patient had worked as a dentist, dental hygienist, or dental technician; among these patients, eight (0.9%) were identified as dentists and one (0.1%) as a dental technician, and each had sought treatment during 2000–2015. Seven of these nine patients had died. A questionnaire was administered to one of the living patients, who reported polishing dental appliances and preparing amalgams and impressions without respiratory protection. Substances used during these tasks contained silica, polyvinyl siloxane, alginate, and other compounds with known or potential respiratory toxicity. Although no clear etiologies for this cluster exist, occupational exposures possibly contributed. This cluster of IPF cases reinforces the need to understand further the unique occupational exposures of dental personnel and the association between these exposures and the risk for developing IPF so that appropriate strategies can be developed for the prevention of potentially harmful exposures.

IPF is a form of chronic, progressive fibrosing interstitial pneumonia of unknown cause. IPF is associated with histopathologic and radiologic patterns of usual interstitial pneumonia in the absence of other known causes of interstitial lung disease (1) and is characterized by unexplained slowly progressive dyspnea that can be accompanied by a nonproductive cough (2). Available treatment options for IPF include pharmacotherapy (i.e., pirfenidone and nintedanib) and lung transplantation (2). The estimated median survival after diagnosis is 3–5 years (2). Although the etiology of IPF is unknown, exposures that have been suggested as contributing factors include viral infections, cigarette smoking, and occupations where exposure to dust, wood dust, and metal dust are common (2). In the United States, on the basis of the case definitions used by separate studies to analyze data collected during 1988–2005, the estimated annual incidence of IPF varied from 6.8 to 17.4 per 100,000 population, and the estimated prevalence varied from 14.0 to 63.0 per 100,000 population (3) and increased with increasing age (2). No published data could be found regarding dental personnel and IPF.

In June 2017, the electronic medical records of all 894 patients with a diagnosis of IPF treated at the Virginia specialty clinic during September 1996–June 2017 were reviewed to identify patients having the occupation of dentist, dental hygienist, or dental technician. Available electronic medical records of patients identified as having one of these occupations were reviewed, pertinent data were abstracted, and an attempt was made to interview living patients to ascertain symptoms and occupational and nonoccupational exposures, after obtaining informed consent. This study received approval from the Inova Fairfax Hospital Institutional Review Board.

Among 894 patients treated for IPF at the tertiary care center, nine (1%) were identified as dental personnel, including eight dentists and one dental technician. All patients were male and were treated during 2000–2015. Five were white, one was black, and the race of three was unknown. At the time of pulmonary consultation, the median patient age was 64 years (range = 49–81 years) (Table). States of residence included Virginia (five), Maryland (three), and Georgia (one). Seven of the nine patients had died; among these, the median survival time from consultation was 3 years (range = 1–7 years). Among eight patients tested at the time of pulmonary consultation, pulmonary function tests demonstrated three patients had normal spirometry, two of whom also had documented normal lung volumes, and five patients had restrictive spirometry and low lung volumes, interpreted as lung restriction. Each of the five patients with restriction had low predicted values for diffusing capacity of the lungs for carbon monoxide (DLCO) (median = 47% [range = 19%–55%]). Pulmonary function test results were not available for one patient. One of the living patients who did not complete an interview underwent a lung transplant 3 years after diagnosis. No tissue specimens were available for analysis.

Three patients were former smokers, one had never smoked, and smoking history was unknown for five (Table). A telephone interview was conducted with the patient who had contacted CDC; it was not possible to complete an interview with the other living patient. The interviewed patient, who had never smoked, reported not wearing a National Institute for Occupational Safety and Health-certified respirator during dental activities throughout his 40-year dental practice; he wore a surgical mask for the last 20 years of his dental practice. He reported performing polishing of dental appliances, preparing amalgams and impressions, and developing x-rays using film developing solutions. He also reported work-related exposure to dust while working as a street sweeper for 3 months before entering dental school and environmental exposure to dust from coral beaches for approximately 15 years while intermittently visiting the Caribbean region as a practicing dentist.
 
Discussion
During September 1996–June 2017, nine (1%) of 894 patients treated for IPF at a single tertiary care center in Virginia were identified as dental personnel. Each patient presented for care during 2000–2015. Seven of the patients had died. This is the first known described cluster of IPF occurring among dental personnel. Although no clear etiology exists for this cluster, it is possible that occupational exposures contributed to the development of IPF.

During 2016, dentists accounted for an estimated 0.038% of U.S. residents (4), yet represented 0.893% of patients undergoing treatment for IPF at one tertiary care center, nearly a 23-fold difference. Dental personnel are exposed to infectious agents, chemicals, airborne particulates, ionizing radiation, and other potentially hazardous materials (5). Inhalational exposures experienced by dentists likely increase their risk for certain work-related respiratory diseases. For example, cases of dental technicians with pneumoconiosis, a restrictive occupational lung disease resulting from inhalation of dust, have been identified after exposure to either silica or cobalt-chromium-molybdenum-based dental prostheses (6,7). A case of pneumoconiosis was identified postmortem in an elderly dentist who died from respiratory failure (8). Examination of lung tissue at autopsy using scanning electron microscopy revealed particles consistent with alginate impression powders used during the dentist’s practice. Nine cases of silicosis were recognized among dental laboratory technicians exposed to crystalline silica in five states during 1994–2000 (9). Asbestos-related lung disease, attributed to manipulating wet asbestos-containing paper during preparation of molds in casting operations, has also been identified in dentists (10). The one living patient in this cluster who was interviewed reported occupational exposures to silica and other materials used in dental practice, but also other work-related and environmental exposures to dust.

IPF has not been previously described among dental personnel. However, a query of the National Occupational Respiratory Mortality System for 4 separate years (1999, 2003, 2004, and 2007) for “other interstitial pulmonary diseases with fibrosis”* (which would include IPF) listed as the underlying or contributing cause of death revealed 35 decedents categorized as having worked in the “office of dentists” and 19 categorized as having the occupation “dentist,” with proportionate mortality ratios of 1.52 (95% confidence interval [CI] = 1.05–2.11) and 1.67 (95% CI = 1.01–2.61), respectively (Respiratory Health Division, CDC, unpublished data, 2017). These findings suggest that a higher rate of IPF might occur among dental personnel than among the general population.

The living patient who was interviewed reported occupational exposures to known respiratory hazards (e.g., silica) yet did not wear National Institute for Occupational Safety and Health-certified respiratory protection. It is possible other patients in this case series had similar experiences. Dental personnel who perform tasks that result in occupational exposures to known respiratory hazards should wear adequate respiratory protection if other controls (e.g., improved ventilation) are not practical or effective (https://www.osha.gov/SLTC/respiratoryprotection/index.html). If respiratory protection is used, a written respiratory protection program should be implemented as required by the Occupational Safety and Health Administration Respiratory Protection Standard, including training, fit testing, and maintenance and use requirements (https://www.osha.gov/pls/oshaweb/owadisp.show_document?p_id=12716&p_table=STANDARDS).

The findings in this report are subject to at least four limitations. First, in this analysis, only patients undergoing treatment at a single tertiary care center specializing in IPF treatment were identified, which might have led to an overrepresentation of dentists, given their comparatively high socioeconomic status. Conversely, dental personnel in Virginia and the surrounding region undergoing IPF treatment at other facilities during this same time frame were not identified, thereby potentially underrepresenting the magnitude of this cluster. Second, only one patient completed an interview, limiting the ability to explore past occupational exposures. Third, multiple patients had reported exposures that occurred outside of work and that are known risk factors for IPF, including tobacco smoke and dust (2). Finally, no biopsy specimens were available for examination to assess histological commonalities among the patients.

This investigation revealed the first described cluster of dental personnel with diagnosed IPF. The eight dentists identified in this cluster exceeded the number of expected cases, consistent with National Occupational Respiratory Mortality System data regarding IPF mortality and the proportion of U.S. residents who are dentists. Dentists and other dental personnel experience unique occupational exposures, including exposure to infectious organisms, dusts, gases, and fumes. It is possible that occupational exposures contributed to this cluster. After this analysis, another IPF case was diagnosed in a dentist treated at this specialty clinic. Further investigation of the risk for dental personnel and IPF is warranted to develop strategies for prevention of potentially harmful exposures.
 
Acknowledgments
John Wood, Respiratory Health Division, National Institute for Occupational Safety and Health, CDC.

Monday, March 19, 2018

Clinical Evaluation of Goby Toothbrush in Progress

Goby all black.png
 
While strolling the aisles of the Chicago Dental Society’s Annual MidWinter Meeting, I came across a small booth for a company called Goby.
 
I had heard about Goby and their cool powered toothbrush before, but I had never had a chance to actually get my hands on one.  The folks at the booth were energetic and friendly and they told me a bit about Goby and their mission as a company.
 
Basically the company believes that a good quality powered toothbrush shouldn’t be a tremendously expensive item.  To that end, they are selling their brushes for $50 to $60 depending on the color.  They have an all black kit (pictured above and *surprise* my personal favorite) and an all pink both for $60 and a white version for $50.
 
Devices like this are a perfect fit into my ‘wheelhouse’ as they help both dentists and patients while providing great technology.  I haven’t used a manual brush for at least a decade and I would never go back.  We don’t sell brushes in our office, but we are always recommending powered brushes to our patients.  Of course the #1 pushback we receive is the cost of the brush.  Goby caught my eye because it’s a powered brush that the company is making an effort to keep affordable.
 
On Thursday, my all black Goby arrived!  So, for the next 4 weeks or so, I’m going to be using it and I’ll report back on my experiences.
 

Thursday, March 15, 2018

Ultradent Announces Special Event: Icons of Dentistry: A Workshop for Women

iod_logo.png
 

Last year, my business partner Dr. John Huebner and I were fortunate enough to be part of Ultradent’s Women in Dentistry Meeting.  It was a really great event and in addition to learning a bunch, we also had a really great time.  Needless to say we’re both pretty fired up about this year’s event being held in South Jordan, Utah at Ultradent’s World Headquarters.  All the details are listed below.  If you have the dates available, I highly recommend you attend! 

Here is the announcement from Ultradent:

In honor of International Women’s Day, Ultradent is pleased to announce an upcoming special two-day event, Icons of Dentistry: A Workshop for Women. It is a weekend of networking, socializing, rejuvenation, and education to celebrate women in dentistry. This year’s theme for the workshop will be Compassion.

The Icons of Dentistry: A Workshop for Women event will take place June 22–23, 2018 at Ultradent’s international headquarters in South Jordan, UT. It will feature iconic women in the field of dentistry teaching classes and workshops on everything from work/life balance, practice building and management, esthetic dentistry, lasers, and more. There will also be a special keynote speaker to be announced later this month.

Attendees will be treated to a special dinner in an orchard at the home of Dr. Dan Fischer, founder and CEO of Ultradent, as well as a cocktail social where attendees can mingle with each other and the event’s speakers. Additionally, attendees will be treated to an evening of dinner and drinks at one of Utah’s highest-rated restaurants, Tuscany.

By attending Icons of Dentistry: A Workshop for Women, clinicians will earn 16 continuing education credits. Registration begins March 8, 2018, with 100 spots available. Tickets are $199.

To register for, or learn more about Icons of Dentistry: A Workshop for Women, please call 800.520.6640 or visit www.iconsofdentistry.com.

***
About Ultradent Products, Inc.
Ultradent Products, Inc. is a leading developer of high-tech dental materials, devices and instruments worldwide. Ultradent’s mission is to improve the level of dental health care and to make dental procedures more predictable and hassle free. Consistent with its mission, Ultradent works to improve the quality of life and health of individuals through financial and charitable programs. For more information about Ultradent, call 800.552.5512 or visit ultradent.com.

Wednesday, March 14, 2018

Colgate® Announces Recipients of the CARE Grant Program Colgate Award for Research Excellence

 

NewImage.png

Colgate is pleased to announce this year’s recipients of the Colgate Award for Research Excellence (CARE). The CARE Program recognizes a new generation of academic researchers by providing up to $30,000 USD (per project) to support oral health research projects across multiple disciplines.

The five proposals were selected by an esteemed group of senior academic dental researchers from a large pool of submissions. The five researchers to receive Colgate’s CARE program funding this year are:

Dr. Jin-Hee Kwak—University of California at Los Angeles (UCLA), School of Dentistry Research Topic: “ BP-NELL-PEG Therapy to Regenerate Craniofacial Bones.”


Dr. Kuei-Ling (Christine) Hsu—University of Maryland, School of Dentistry
Research Topic: “Transcriptomic and Metabolomic Profiling of the Oral Microbiome in Socially Disadvantage African American Children with Early Childhood Caries.”


Dr. Tamanna Tiwari—University of Colorado, School of Dental Medicine 
Research Topic: “A Participatory Approach in Improving Dental Health in African Immigrants.”

Dr. David Prince—Roseman University, College of Dental Medicine  
Research Topic: “Silver Diamine Fluoride and the Elderly.”

Dr. Cristina Vidal—University of Iowa, College of Dentistry 
Research Topic: “Development of Therapeutic Nanoparticles for Sustained Delivery of Proanthocyanidins in Adhesive Interfaces.”

Proposals were reviewed by a panel of independent reviewers who are non-Colgate researchers. Winners were selected based on program criteria which included innovation, clinical significance, originality and scientific quality. CARE grants are typically offered for periods of 12 months.

“The CARE Program fosters the development of junior faculty by providing seed research funding to emerging leaders in academia at a time in their career path when it is most needed,” said Maria Ryan, Vice President and Chief Dental Officer, Global Technology at Colgate. “Every year, we look forward to meeting and supporting talented researchers in the early stages of their careers by helping to fund innovative projects that promise to advance industry knowledge and perhaps even revolutionize the field of dentistry. On behalf of Colgate, sincere congratulations to the winners of this year’s grant awards.”

Established in 2016, the Colgate CARE Program is designed to foster clinical and scientific research by providing financial support to young academic researchers. In order to be eligible for the Colgate CARE grant, faculty applicants must be in the first five years of an academic appointment.

For more information about the Colgate CARE Program for Young Academic Researchers and application guidelines, click here or visit ColgateProfessional.com/research.

ABOUT COLGATE-PALMOLIVE

Colgate-Palmolive is a leading global consumer products company, tightly focused on Oral Care, Personal Care, Home Care and Pet Nutrition. Colgate sells its products in over 200 countries and territories around the world under such internationally recognized brand names as Colgate, Palmolive, Speed Stick, Lady Speed Stick, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, Elmex, Meridol, Tom’s of Maine, Sanex, Ajax, Axion, Fabuloso, Soupline and Suavitel, as well as Hill’s Science Diet, Hill’s Prescription Diet and Hill’s Ideal Balance. For more information about Colgate’s global business, visit the Company’s web site at http://www.colgatepalmolive.com. To learn more about Colgate Bright Smiles, Bright Futures® oral health education program, please visit http://www.colgatebsbf.com.CL-C

Tuesday, March 13, 2018

Darby Dental Supply Launches New Surgical Division

 

NewImage.png

Darby Dental Supply, one of the nation’s largest dental distributors, announces the launch of a new surgical division. The comprehensive division encompasses over 5,000 top-tier branded products in categories such as instrumentation, sutures, bone grafting, and other surgical-specific areas.

To accommodate the new division, Darby hired a dedicated team of Surgical Account Managers, each of whom have undergone a full year of specialized surgical product training in order to provide expert customer service and knowledge regarding dental surgery and implant procedures.

“In the past, customers in the oral surgery space might have had to call one company for surgical instrumentation, another for bone grafting, a third for sutures, and sometimes others just to fulfill all their surgical needs,” stated Brian Kacerow, Surgical Category Manager, Darby Dental Supply. “Darby’s surgical division eliminates the inconvenience of shopping around by providing a one-stop shop for GPs, Implantologists, and Surgical Specialists.”

The new division is the latest in Darby’s expansion into a full-service solutions provider, further meeting the needs of general practitioners and specialists by adding to the Company’s growing ecosystem of offerings. The Company recently expanded its capital equipment division, formed an exclusive partnership with Dental Fix Rx to provide equipment service, and launched Darby TechForce®, the Company’s new technology services division providing HIPAA compliance, IT managed services, installations, digital integration, and network security solutions.

For more information on Darby’s surgical division as well as its ever-expanding solutions for dental professionals nationwide, please visit www.darby.com.

Monday, March 12, 2018

The Dental Industry’s Only News Aggregation And Social Engagement Forum App Launches To Simplify Life and Connect Users

SWYP Dental.png
 

The concept of “news aggregators” has been around for a while now.  However, many of them are no longer around, and those that remain are a bit clunky and not very specific.  However, a new company has come to market with an aggregator that is specific to the dental industry.  It’s called SWYP and is available now.  The service is device agnostic, meaning you can access their website or use apps for Android or iOS to get to the content.

 

 

Designed for busy dental professionals using mobile devices and tablets, SWYP Dental transforms the reading, learning, and social media experience

 – SWYP Dental simply and elegantly combines the beauty of print magazines with the power and convenience of digital and social media. SWYP collects dental content (articles, news, blogs, podcasts) based on user-selected preferences and then delivers the customized content in an App or desktop website. Free to download, SWYP is for all dental professionals including dentists, dental assistants, hygienists, office managers, dental labs, industry professionals, and more. It will revolutionize and transform the way dental professionals consume information.

SWYP contains content from around the dental web on topics you’d expect like Digital Dentistry, Hygiene, Practice Management, and more. It even mixes in topics from outside the industry like finance, business ownership, internet marketing, motivating employees, health & fitness, travel, and more.

“We’re solving the problem of information overload that plagues us all. No one has time for content they aren’t interested in”, states Matthew Petchel, SWYP CEO. “SWYP solves that problem because our users only see content they are interested in based on their preferences and behavior in the app. The future isn’t about spending time looking for content. The future is about having interesting, relevant, and timely content finding you. Think of SWYP as a targeted information funnel for the entire dental industry.”

SWYP also share totally original content from the next wave of influencers to give a more complete, up-to-date view of the dental industry. In addition, SWYP has a community Q&A Forum for users to ask questions and engage with one another to earn points redeemable for rewards. SWYP is also ‘the dental search engine’ that delivers the most relevant results for dental topics. Dental professionals can finally focus all of their attention on the specific information they want to help them be a better dentist, a better hygienist or assistant, and better business leader.

SWYP was founded by industry veterans; Tony Stefanou, Ekram Khan, Jim Arnold, and Matthew Petchel with a combined 97 years in the dental industry. Their experience combines clinical, marketing, industry, and technology expertise.

SWYP is available for both iOS and Android devices and can be downloaded at http://www.SWYPdental.com

SWYPDental everything…all in one app™.

####

About SWYP
SWYP is a community of dental professionals that lives and breathes within a mobile app and desktop website. SWYP is a Dental News Aggregator and Q&A Community Forum combined and targeted to the dental industry.
SWYP – Dental everything…all in one app™

Thursday, March 8, 2018

KemPharm Announces FDA Approval of Apadaz™ (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain

KenPharm Logo.jpeg
 

Apadaz is the First Prodrug of Hydrocodone/Acetaminophen to be Approved by FDA

 

CORALVILLE, Iowa, Feb. 23, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for Apadaz™ for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.  Apadaz is an immediate release (IR) combination of KemPharm’s prodrug, benzhydrocodone, and acetaminophen (APAP).  

“The approval of Apadaz is a significant milestone for KemPharm as it creates the opportunity to introduce what we believe is a differentiated product for the short-term management of acute pain,” said Travis Mickle, Ph.D., KemPharm President and Chief Executive Officer.  “Based on its unique properties, we firmly believe there is a commercial pathway for Apadaz in what is a very high-volume market.  We are excited by the opportunity Apadaz offers to patients and for physicians who now have the option of prescribing a differentiated product.”

“In addition to today’s approval, the U.S. Drug Enforcement Administration (DEA) has indicated that it is their intent to schedule Apadaz as a C-II product and will provide an allocation of the Active Pharmaceutical Ingredient (API) consistent with those scheduling provisions,” added Dr. Mickle.  “This prompt decision by the DEA essentially completes the regulatory process with both Agencies and allows us to shift our focus towards the product launch.”

“Finally, today is a validation of KemPharm’s groundbreaking LATTM (Ligand Activated Therapy) platform and our technological approach to drug development,” Dr. Mickle closed.  “KemPharm is first and foremost a prodrug development company.  The Apadaz approval highlights the value potential that LAT™ offers in the discovery and development of proprietary prodrugs that are designed to be differentiated versions of widely prescribed, currently approved drugs, and that can successfully complete the rigorous regulatory process.”

APADAZ™

Apadaz was developed from KemPharm’s proprietary LATTM (Ligand Activated Therapy) platform technology and is intended for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. KemPharm believes Apadaz is unique among prescription opioids in that it contains a prodrug that is chemically inert, or inactive, on its own.  When ingested, enzymes in the gastrointestinal tract cleave the ligand from the prodrug (benzhydrocodone) and release the parent drug (hydrocodone), which can then exert its therapeutic effect.  The final approved product labeling for Apadaz includes these and other data points but concludes that the overall results of the clinical program did not demonstrate abuse-deterrence by current measurement standards.

The approval of Apadaz via the 505(b)(2) pathway was based in part on pharmacokinetic studies with Vicoprofen®, Ultracet®, and Norco® in which Apadaz demonstrated exposure to hydrocodone and acetaminophen (APAP) that is expected to result in therapeutic effects equivalent to currently approved immediate-release hydrocodone/APAP combination products when administered orally as intended.

Indication:
Apadaz contains an opioid agonist and acetaminophen and is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve Apadaz for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] have not been or are not expected tolerated, or have not provided adequate analgesia, or are not expected to provide adequate analgesia.

Important Safety Information:

Apadaz is contraindicated in patients with: significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; and hypersensitivity to hydrocodone or acetaminophen.

Apadaz contains benzhydrocodone, a Schedule II controlled substance.  Apadaz can be abused and is subject to misuse, addiction, and criminal diversion.

Potential risks associated with Apadaz include addiction, abuse, and misuse, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, risks of concomitant use or discontinuation of cytochrome P450 CYP3A4 inhibitors and inducers, acetaminophen hepatoxicity risks from concomitant use with benzodiazepines or other CNS depressants, risk of life-threatening respiratory depression in patients with chronic pulmonary disease or in elderly, cachectic, or debilitated patients, adrenal insufficiency, severe hypotension, serious skin reactions, risks of use in patients with increased intracranial pressure, brain tumors, head injury, or impaired consciousness, hypersensitivity/anaphylaxis, risks of use in patients with gastrointestinal conditions, risk of use in patients with seizure disorders, and withdrawal, risks of driving and operating machinery. 

Potential drug interactions with Apadaz include:

Serotonergic Drugs: Concomitant use may result in serotonin syndrome.  Discontinue Apadaz if serotonin syndrome is suspected.
Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics: Avoid use with Apadaz because they may reduce analgesic effect of APADAZ or precipitate withdrawal symptoms.
Monoamine Oxidase Inhibitors (MAOIs): Can potentiate the effects of hydrocodone. Avoid concomitant use in patients receiving MAOIs or within 14 days of stopping treatment with an MAOI.
Most common adverse reactions (>5%) are nausea, somnolence, vomiting, constipation, pruritus, dizziness, and headache.

The Full Prescribing Information for Apadaz contains the following Boxed Warning:

WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; CYTOCHROME P450 3A4 INTERACTION; HEPATOTOXICITY; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS

Addiction, Abuse, and Misuse:

Apadaz exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing Apadaz and monitor all patients regularly for the development of these behaviors and conditions.

Life-Threatening Respiratory Depression:

Serious, life-threatening, or fatal respiratory depression may occur with use of Apadaz.  Monitor for respiratory depression, especially during initiation of Apadaz or following a dose increase.

Accidental Ingestion:

Accidental ingestion of even one dose of Apadaz, especially by children, can result in a fatal overdose of hydrocodone.

Neonatal Opioid Withdrawal Syndrome:

Prolonged use of Apadaz during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts.  If prolonged opioid use is required in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Cytochrome P450 3A4 Interaction:

The concomitant use of Apadaz with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Monitor patients receiving Apadaz and any CYP3A4 inhibitor or inducer.

Hepatotoxicity:

Apadaz contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product.

Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants:

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.

Reserve concomitant prescribing of Apadaz and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate.
Limit dosages and durations to the minimum required.
Follow patients for signs and symptoms of respiratory depression and sedation.
For Important Safety Information including full prescribing information, visit: www.kempharm.com

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LATTM (Ligand Activated Therapy) platform technology.  KemPharm utilizes its proprietary LATTM platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of ADHD, pain and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release/effect profiles for the treatment of ADHD.  In addition, the company has received FDA approval for Apadaz™, an immediate-release combination product candidate of benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.  The company is also advancing KP201/IR, an acetaminophen-free immediate-release formulation of the company’s benzhydrocodone prodrug candidate. Both Apadaz™ and KP201/IR are intended for the treatment of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com.

Caution Concerning Forward Looking Statements:

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm’s business are described in detail in KemPharm's Annual Report on Form 10-K for the year ended December 31, 2016, and KemPharm’s other Periodic and Current Reports filed with the Securities and Exchange Commission.  KemPharm is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Wednesday, March 7, 2018

Ultradent Introduces Peak®-ZM Zirconia and Metal Primer

Peak ZM_Syringe and Bottle_0717.jpg

Ultradent Products, Inc., is pleased to introduce Peak®-ZM zirconia and metal primer. Peak-ZM primer is specifically designed to provide high adhesion between zirconia and metal surfaces and the luting material. Thanks to the chemistry containing the MDP monomer, Peak-ZM primer can increase bond strengths five times compared to using a resin cement alone.1 With Peak-ZM primer, clinicians can feel confident in their zirconia and metal restorations.

Peak-ZM zirconia and metal primer is a single component surface treatment that enhances bond values when applied to zirconia, alumina, and metal/alloys. It contains a blend of monomers, including 10-methacryloyldecyl dihydrogen phosphate (MDP), which produces a chemical bond that significantly increases adhesion between resin-based material and the bonding surface of the restoration. It also features a smart chemistry that includes in-house, custom-synthesized monomers that help enhance its bond strength.

Peak-ZM primer is available in convenient 4 ml bottles (300 uses) and 1.2 ml syringes (100 uses).

To learn more about Peak-ZM primer, call 800.552.5512, or visit ultradent.com.

Tuesday, March 6, 2018

Opalescence® PF Tooth Whitening System Unveils New Packaging

Opalescence PF New Packaging.jpg

Ultradent Products, Inc., is pleased to unveil new packaging for its hallmark professional take-home tooth whitening system, Opalescence® PF whitening. Opalescence PF whitening system’s new look showcases a modern, sophisticated, clean esthetic and utilizes less plastic than its predecessor. The new packaging also features a nesting concept, which maximizes space and gives each product element a designated place for easy access and product storage. The box uses an invisible magnetic closure, making it easy and desirable to save and reuse, adding to the environmentally friendly, contemporary appeal.

The Opalescence PF tooth whitening system has ranked as the number one professional whitening system worldwide since its release in 1990. The award-winning system features customized take-home whitening trays with syringe-delivered whitening gel. Opalescence whitening gel is known for its sticky, viscous texture which allows it to stay put on the tooth instead of migrating to tissues to provide maximum whitening results with minimum sensitivity. Newest to the Opalescence PF whitening brand is Opalescence® Quick—a 45% carbamide peroxide whitening gel with a 15–30-minute wear time that is now part of Opalescence PF’s take-home line of products. It comes in a Mint flavor. PF whitening also comes in 10%, 15%, 20%, and 35% carbamide peroxide concentrations, in both Regular, Mint, and Melon flavors. The product also contains potassium nitrate and fluoride.

Opalescence PF tooth whitening system is recommended for whitening discolored teeth prior to placement of composite, veneers, or crowns. It is effective in removing some or all internal tooth discolorations due to congenital, systemic, pharmacologic, and traumatic factors, as well as aging. It has even been successful in resolving staining due to fluorosis and tetracycline.1,2


To learn more about Opalescence PF tooth whitening system and to check out its new packaging, visit the Ultradent Booth #3811 at the 2018 Chicago Midwinter Show, call 800.552.5512, or visit ultradent.com.
About Ultradent Products, Inc.
Ultradent Products, Inc., is a leading developer and manufacturer of high-tech dental materials, devices, and instruments worldwide. Ultradent’s vision is to improve oral health globally. Ultradent also works to improve the quality of life and health of individuals through financial and charitable programs. For more information about Ultradent, call 800.552.5512 or visit ultradent.com.

Monday, March 5, 2018

Darby Dental Supply Continues West Coast Expansion with Acquisition of SmartPractice® Dental Supply Division

Darby Logo.jpeg

 

Darby Dental Supply, one of the nation’s largest dental distributors, announces its planned acquisition of the dental supply division of Phoenix-based SmartPractice.
This acquisition and the resulting strategic partnership capitalize on each company’s core competencies with Darby leveraging SmartPractice’s acclaimed glove expertise and manufacturing capabilities. SmartPractice’s supply and glove customer base will benefit from Darby’s expansive state-of-the-art distribution network, extended product lines, capital equipment, technology services, and equipment service.
The agreement with SmartPractice is Darby’s latest endeavor to partner with companies who have select areas of industry expertise. Darby customers will gain direct access to SmartPractice’s premier line of specialized gloves.


With this acquisition, Darby will be expanding its Chandler, Arizona facility to provide customers with additional services while extending its hours of operation. Additional sales, customer care, and support services will join the Arizona team to provide convenient access for customers across the country. The transaction fuels Darby’s growth strategy to extend its ecosystem of full service solutions, while supporting its ongoing West Coast expansion.


“This investment further strengthens Darby Dental Supply’s position as an industry leader and ensures that our customers have access to continually-expanding products, advanced services, and the expertise upon which they have relied for 70 years,” stated Michael Ashkin, Chairman, Darby Group Companies, Inc. “For three generations, and looking to the fourth, the Ashkin family has been focused on providing our customers with outstanding value, an exceptional customer experience, and innovative technological solutions. This would not be possible without the hard work of our talented employees. We are excited to welcome the SmartPractice dental supply team into our extended family.”


“With our rich history of accomplishments for nearly 50 years, SmartPractice has only just begun to realize our full potential of improving healthcare practices to improve world health. Through this strategic relationship, Darby Dental will be partnering with us as an additional provider of SmartPractice gloves to the dental industry. Our legacy of pioneering award-winning gloves that meet the unique needs of the dental community will now have a broader reach,” remarked Dr. Curt Hamann, President, CEO, and Medical Director of SmartPractice. "Additionally, our team continues to capitalize on our existing resources to develop an array of products and services that improve active patient counts, simplify brand management and ensure an easy ordering experience."


Darby has consistently advanced its business model to meet customer demand for timely, best-in-class solutions. The company recently expanded its specialty product offerings, added a capital equipment division, formed an exclusive partnership with DentalFix RX to provide equipment service, and in January 2018 debuted Darby TechForce®, the company’s new technology services division providing HIPAA compliance, IT managed services, installations, digital integration, and network security solutions. As customers seek out more convenient ordering channels and faster response times, Darby’s investment in technological solutions allows them to personalize the way they do business. The Company recently launched a new user-optimized website, mobile website, and a mobile app, complete with an inventory management system.
The transaction is expected to close in May of 2018.

About Darby Dental Supply, LLC
Darby Dental Supply, LLC, is one of the largest dental distributors in the United States, shipping over one million orders each year. Headquartered in Jericho, NY, the company was founded in 1948 and has seven sales offices and three fully-automated distribution centers strategically positioned across the country. With over 45,000 products in stock, Darby services the general practitioner as well as numerous specialties. In addition to Darby’s supply vertical, the company also hosts a technology services division (Darby TechForce®), a capital equipment division, equipment repair services (through an exclusive partnership with DentalFix RX), and a full line of private label products. For more information about Darby, please visit www.darby.com.

About SmartPractice
SmartPractice® is a family-owned company serving dental, veterinary, dermatology, allergy and healthcare professionals globally with patient communications, practice marketing, exam gloves and medical supplies that include T.R.U.E TEST and other skin patch testing supplies. Since 1969, the Phoenix, AZ-based company has been driven by its mission for healthier practices and healthier patients. The company has received consecutive national awards for its innovative glove solutions, print manufacturing excellence, corporate philanthropy and employee wellness programs. For more information about SmartPractice, visit www.smartpractice.com.

Thursday, March 1, 2018

Introducing DEXIS FS Ergo by KaVo – A New Class of Digital Sensors

Kavo FS Ergo.jpg
 
Have you ever wanted a more comfortable digital x-ray sensor?  I think that’s a question that lots of dentists and staff ask themselves.  Now DEXIS has introduced the DEXIS FS Ergo, which looks to be the next big thing in digital radiography.  Read on for all the details!
 

KaVo Kerr, an organization comprised of two global leaders in dentistry, is pleased to unveil the expansion of its growing portfolio of imaging solutions at this year’s Chicago Midwinter dental meeting with the new DEXIS FS Ergo by KaVo. Built upon the award-winning DEXIS PerfectSize™sensor and TrueComfort™ design, the FS Ergo stands as the latest innovation to redefine patient comfort and create a new class of digital sensors. FS Ergo combines innovative design and skillfully engineered components to add ease and flexibility to thepatient experience. The sensor provides significant improvements in comfort for patients with low tolerance for standard intraoral modalities, allowing for a more pleasant sensor placement that patients will remember.

A robust, durable device that maintains optimal image integrity, FS Ergo features:

  • Sensor Housing – resistant to bite marks, the submersible sensor housing can also withstand a wide variety of disinfection chemicals.
  • Cable-To-Sensor Connection – equipped with connectivity proven successful under rigorous testing to such forces as pulling, twisting, straining, and bending.
  • USB Connector – built to withstand high frequency insertion and pulling cycles, the USB connection adds to the overall durability of the sensor.
  • Contoured Positioning System – made from advanced materials, the positioning system allows the sensor to easily exit and protects the longevity of the cable from wear and tear.

DEXIS FS Ergo by KaVo helps to reduce retakes due to patient movement caused by discomfort thereby enhancing practice efficiency and creating a streamlined digital workflow. By pairing the newly developed flexible sensor technology with a soft housing, FS Ergo can “give” as X-rays are being captured. Even the proprietary holder system is uniquely designed to accommodate the flex of the sensor so that it can adapt to your patient, and thus offer the best radiographic experience possible. “DEXIS products have always instilled confidence in patients and practitioners, and FS Ergo by KaVo will reinforce their beliefs,” stated Insiyah Ahmedi, Sr. Marketing Manager, KaVo Kerr Intraoral Imaging. “The complete line of DEXIS imaging products has continually displayed the ability to innovate and excite with digital solutions that consistently provide highly diagnostic information crucial for patient care." Dental professionals are encouraged to experience how the FS Ergo can work for them.

 

To learn more about the DEXIS FS Ergo by KaVo, please visit www.dexis.com/fs-ergo